FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Article

Source CRWESelect : CNIT, PWRM.OB, NKBP, CPGI, - China Information Technology, Power3 Medical Products, China Nuokang Bio-Pharma

Posted, by CRWESelect Stoc... on December 15th, 2010

China Information Technology, Inc. (NASDAQ:CNIT) a leading total solutions provider of geographic information systems (GIS), digital public security technology (DPST) and digital hospital information systems (DHIS) in China, announced it ranked among the Deloitte Technology Fast 500 Asia Pacific, for the third consecutive year. The Deloitte Technology Fast 500 Asia Pacific recognizes the 500 fastest growing Asia Pacific-based technology companies. Rankings are based on percentage revenue growth over the past three years. Remaining on the prestigious list for the third year, CNIT proved itself to be one of the fastest growing software-based companies in the region, and a leading company with intellectual property-driven revenue growth in China.

China Information Technology, Inc. specializes in Geographic Information System (GIS), digital public security, and hospital information systems in China.

****

Power3 Medical Products, Inc. (PWRM.OB) - Breast cancer is a type of cancer where cells in the breast divide and grow without normal control. About 85 percent of breast cancers begin in the mammary ducts, while about 15 percent arise in the lobules. Tumors in the breast tend to grow slowly. By the time a lump is large enough to feel, it may have been growing for as long as 10 years. However, some tumors can be aggressive, and grow much more rapidly.

PWRM is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).

Amyotrophic lateral sclerosis (abbreviated ALS, also referred to as Lou Gehrig's disease) is a form of motor neuron disease. ALS is a progressive,[1] fatal, neurodegenerative disease caused by the degeneration of motor neurons, the nerve cells in the central nervous system that control voluntary muscle movement. The condition is often called Lou Gehrig's disease in North America, after the famous New York Yankees baseball player who was diagnosed with the disease in 1939.

Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, for which it is currently engaged in Phase II clinical trials. The tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

For more information about this company please visit http://www.power3medical.com

****

China Nuokang Bio-Pharmaceutical Inc. (NASDAQ:NKBP) a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, announced its participation in the 29th Annual J.P. Morgan Healthcare Conference, to be held January 10-13, 2011 at the Westin St. Francis Hotel in San Francisco. The China Healthcare Track of the conference will be held on January 12, 2010. Management will meet with institutional investors throughout the duration of the conference.

China Nuokang Bio-Pharmaceutical Inc., a biopharmaceutical company, focuses on the research, development, manufacture, marketing, and sale of hospital-based medical products in China.

****

China Shengda Packaging Group, (NASDAQ:CPGI) a leading Chinese paper packaging manufacturer, announced the pricing of an underwritten public offering of 8,145,631 shares of its common stock at a public offering price of $4.00 per share. Of these shares, 8,000,000 are being sold by the Company and 145,631 are being sold by a selling stockholder. The offering is expected to close on or about December 15, 2010, subject to customary closing conditions. The Company has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock to cover over-allotments.

China Shengda Packaging Group Inc. engages in the design, manufacture, and sale of paper cartons and packaging solutions to consumer and industrial goods manufacturing companies in the Peoples Republic of China.

CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the move.

Sign Up for our Free Stock Newsletter at http://www.crweselect.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).

PWRMcrweselect1215

READ MORE AT: 
http://crweselect.com/
Authored by, CRWESelect Stoc...
Log in or register to post Private Message
Advertise with us

Add new comment